Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study
about
Genome of the Bacterium Streptococcus pneumoniae Strain R6Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitisAdenoid reservoir for pathogenic biofilm bacteria.Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States.Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States.In vitro and In vivo activities of LB 10827, a new oral cephalosporin, against respiratory pathogensEvaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.Identification of beta-lactamase-negative, ampicillin-resistant strains of Haemophilus influenzae with four methods and eight mediaHigh prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study).Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitisActivity of daptomycin against recent North American isolates of Streptococcus pneumoniaeClinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaxime.Macrolide resistance in Streptococcus pneumoniae: Fallacy or fact?OTO-201: nonclinical assessment of a sustained-release ciprofloxacin hydrogel for the treatment of otitis media.Etiology and Anti-microbial Sensitivity of Organisms Causing Community Acquired Pneumonia: A Single Hospital Study.Identification of a hemin utilization protein of Moraxella catarrhalis (HumA).Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations.Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model.In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations.Factors influencing fluoroquinolone resistance.Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999).Levofloxacin-resistant Streptococcus pneumoniae: second look.
P2860
Q22065464-8D32EC7B-E47D-4680-A1E8-BD1F06081ACEQ33241517-BF7462F9-B834-4139-9A56-EA15C0B849B1Q33816610-27290FE3-1A0A-4257-AA54-6B6BA6BD87B3Q33836773-89B84849-1468-43D3-A615-485F6C875084Q33980574-25BD2108-4168-4949-A99D-9014B86BBECBQ33980926-9ED60E9D-C0F9-4DF9-9E73-3824BEFE944BQ33981224-BC5054B7-DBA1-4ABD-B204-5B5831BE232CQ33981554-0802B7AE-B6AB-4FD0-9F1F-A43D7A670511Q33982149-60F5E8A4-AB12-4367-9D15-7FED3BE2088CQ34141387-100CFC77-DEE2-4F10-B106-2E0A53204B04Q35013962-11ECC6EE-5647-45B9-AD7E-494F3F57C17BQ35014040-EED6C0D2-5FCC-49AB-AD00-AEA47EFAD757Q35685125-2D3650CE-90D3-4B04-AEF8-0867E20B6610Q35685343-3CFDD917-6D2F-42A3-8B09-DA6625861E1FQ36048514-0C1E175E-79EA-4235-9079-D0B9AE01AD33Q36170473-95B7BFFD-671F-4A65-ABE6-CE46E75DBB3FQ36903916-00E93D63-3B42-42DC-9EB7-7CA2D0A1D87BQ37517821-8D4F259B-75C0-4E3C-84C4-EF5AD7AEF308Q37582884-E4781A22-E1F0-4557-93B8-1C00B35EDCFBQ39671236-6CD0EA17-DF18-4F9F-A2D7-C13C769A9540Q39740481-B934CDB5-2122-48CB-A80B-DF9D56C0082CQ39746806-A411B382-BA18-40D9-A8BA-783EDEC392C8Q42590584-5D88D385-4311-4810-9DB2-B67C6538D43AQ42727142-68C6E1CD-922C-432B-A8B8-1B87CD9DE016Q42730587-089A0EAC-D130-4738-952E-5821587966D5
P2860
Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Survey of susceptibilities of ...... ents: a prospective U.S. study
@ast
Survey of susceptibilities of ...... ents: a prospective U.S. study
@en
type
label
Survey of susceptibilities of ...... ents: a prospective U.S. study
@ast
Survey of susceptibilities of ...... ents: a prospective U.S. study
@en
prefLabel
Survey of susceptibilities of ...... ents: a prospective U.S. study
@ast
Survey of susceptibilities of ...... ents: a prospective U.S. study
@en
P2093
P2860
P356
P1476
Survey of susceptibilities of ...... ents: a prospective U.S. study
@en
P2093
Holley HP Jr
Ogilvie PT
Thornsberry C
P2860
P304
P356
10.1128/AAC.43.11.2612
P407
P577
1999-11-01T00:00:00Z